Görüntüleme
6
Dapagliflozin kardiyovasküler hastalıklarda güvenli ve yararlı olduğu gösterilen bir oral anti-diyabetik (OAD) ilaçtır. Dapagliflozinin kardiyovasküler olumlu etkilerinin kesin mekanizması tam olarak bilinmemektedir. Bu çalışmada, dapagliflozin kullanan hastalarda tedavinin trombosit fonksiyonunu gösteren ortalama trombosit hacmi (OTH) ve yeni inflamatuar belirteçler olan nötrofil lenfosit oranı (NLO) ve trombosit lenfosit oranı (TLO) üzerine etkilerini araştırmayı amaçladık. Daha önce OAD veya OAD+insülin tedavisi almakta iken tedaviye dapagliflozin eklenen, 18 yaş üstü tip 2 diyabeti olan hastaların dosyaları incelenerek, dapagliflozin tedavisi başlamadan önce ve tedaviden sonra 3-6 ay içindeki laboratuar verileri kaydedildi. Dapagliflozin tedavisi ile birlikte glukoz ve A1c değerleri anlamlı olarak azalırken (her iki p<0.001), hemoglobin, hematokrit ve NLO değerleri anlamlı olarak arttı (sırasıyla p=0.005, p=0.001 ve p=0.032). Ayrıca nötrofil sayısı anlamlı olarak artarken, lenfosit sayısı anlamlı olarak azaldı (p=0.029 ve p=0.019). Dapagliflozin etkili bir OAD olup vücuttaki inflamasyon üzerine etkileri bulunmaktadır. Bu etkinin nasıl ve neden olduğunun anlaşılmasına ihtiyaç vardır.
Dapagliflozin is an oral anti-diabetic drug (OAD) that has been shown to be safe and useful in cardiovascular diseases. The exact mechanism of cardiovascular positive effects of dapagiflozin is not fully understood. In this study, we aimed to investigate the effects of dapagliflozin treatment on average platelet volume (MPV) as the marker of platelet function, and neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) as new anti-inflammatory markers. Laboratory data were recorded before and 3-6 months after the treatment of patients with type 2 diabetes over the age of 18 who received dapagliflozin when receiving OAD or OAD + insulin. Glucose and A1c values were significantly decreased (both p <0. 001) and hemoglobin, hematocrit and NLR values were significantly increased with dapagliflozin treatment (p=0.005, p=0.001 and p=0.032, respectively). In addition, neutrophil count increased significantly and lymphocyte count decreased significantly (p=0.029 and p=0.019). Dapagliflozin is an effective OAD and affects inflammation in the body. There is a need to understand how and why this effect occurs.
Dapagliflozin is an oral anti-diabetic drug (OAD) that has been shown to be safe and useful in cardiovascular diseases. The exact mechanism of cardiovascular positive effects of dapagiflozin is not fully understood. In this study, we aimed to investigate the effects of dapagliflozin treatment on mean platelet volume (MPV) as the marker of platelet function, and neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) as new anti-inflammatory markers. Laboratory data were recorded before and 3-6 months after the treatment of patients with type 2 diabetes over age of 18 years who received dapagliflozin when receiving OAD or OAD + insulin. Glucose and A1c values were significantly decreased (both p <0.001) and hemoglobin, hematocrit and NLR values were significantly increased with dapagliflozin treatment (p=0.005, p=0.001 and p=0.032, respectively). In addition, neutrophil count increased significantly and lymphocyte count decreased significantly (p=0.029 and p=0.019). Dapagliflozin is an effective OAD and affects inflammation in the body. There is a need to understand how and why this effect occurs.
Alan : Sağlık Bilimleri
Dergi Türü : Ulusal
Makale Detay 
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
